Please login to the form below

Not currently logged in
Email:
Password:

Praluent

This page shows the latest Praluent news and features for those working in and with pharma, biotech and healthcare.

Segmentation, evolved

Segmentation, evolved

Sanofi’s Praluent is a good example of this but, as usual, allow me to wander off into the parallels with biological evolution before returning to the practical lessons for our ... Well, it means that we need to pay attention to apparently small

Latest news

More from news
Approximately 20 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    Repatha from Amgen was the first in the class to be approved in Japan in January, although it will likely only be months before Sanofi's rival Praluent will join it

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration ... We are very much encouraging collaboration, so we are

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics